Boehringer Ingelheim Biologicals Development Center (BDC), Biberach

https://www.boehringer-ingelheim.com

In April 2023 Boehringer Ingelheim inaugurated its state-of-the-art Biologicals Development Center (BDC) in Biberach an der Riß, Germany. The new high-tech facility underlines the company’s strong commitment to Germany and Europe as location for research and development (R&D) for the care of patients around the world. With the investment of 350 million EUR, Boehringer Ingelheim significantly enhances its innovation power and development of biopharmaceutical development capabilities in Germany. Biopharmaceuticals are highly complex drugs and at the same time one of the fastest growing drug segments of the pharmaceutical industry. They offer therapies for many indications such as cancer, stroke or heart attack. The new facility is a highly complex building, offering modern workplaces for more than 500 employees who will develop Boehringer Ingelheim's future biopharmaceutical substances. Scientists from multiple disciplines and three different development units will collaborate under one roof to research and develop antibodies and therapeutic proteins. They will have the capability to produce these substances from lab-scale to supply for clinical studies. The BDC is an impressive building with a gross floor space of 34,500 sqm, which equals five football fields. Today’s inauguration is another milestone in the further development of Boehringer Ingelheim’s campus in Biberach, which is the company’s largest R&D and Biopharmaceuticals site with more than 7,000 employees. The construction of the BDC is part of Boehringer Ingelheim's consistent future strategy with significant investments in its R&D pipeline, which amounted to 5 billion EUR in the last business year – 47 percent alone in Germany. *

	Start	2023-04-24 start
	Group	Boehringer Ingelheim (Group)
	Industry	biopharmaceutical
	Industry 2	drug development

	Region	Biberach/Riß
	Country	Germany
	City	88397 Biberach/Riß
		Address record changed: 2023-04-28

Basic data	Employees	n. a.

		* Document for »About Section«: Boehringer Ingelheim. (4/24/23). "Press Release: Boehringer Ingelheim Inaugurates Largest European Development Centre for Biotechnology". Ingelheim.

		Record changed: 2023-12-30

Picture Kenes Exhibitions Biomed Israel 2024 Tel Aviv 650x200px

More documents for Boehringer Ingelheim (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)